ICU Medical (ICUI) 2026 KeyBanc Capital Markets Healthcare Forum summary

Key financial guidance and macro assumptions

• EBITDA guidance for the year set at $400–$430 million, based on stable hospital census and macro factors including tariffs, currency, and fuel prices.

• Tariffs and currency fluctuations are expected to have moderate impact; fuel costs are a headwind but less significant than in prior years.

• Consumables and systems segments are expected to deliver mid-single-digit growth, with some seasonality and back-half weighting.

• Gross margin targeted to reach 41% in 2026, with further expansion to 43% as integration and manufacturing consolidation complete.

• Free cash flow is expected to improve as integration and remediation costs decline, with a goal to reach 2x leverage and return capital to shareholders.

Business segment performance and strategy

• Consumables segment shows consistent growth, driven by brand strength, clinical efficacy, and niche market expansion.

• SKU rationalization in the Vital Care portfolio is underway, focusing on profitability and expected to impact Q1 growth.

• Pump segment growth is supported by new product launches (Plum Solo, Plum Duo), with a focus on upgrading aging installed base and leveraging software integration.

• Ambulatory pump headwinds from an OEM customer are expected to resolve by year-end, improving future segment performance.

• Innovation in consumables is being prioritized, with new product integrations and regulatory submissions in progress.

Integration, portfolio management, and outlook

• Smiths integration is in late stages, with manufacturing, logistics, and IT consolidation nearly complete; benefits expected to materialize in margins and cash flow.

• Portfolio management for non-core assets is ongoing, with a focus on economic efficiency and value preservation.

• Regulatory submissions for new Medfusion and CADD ambulatory pumps are progressing, with constructive feedback and anticipated approvals.

• Software monetization is a strategic focus, aiming to capture annuity revenue from enhanced platforms and add-ons.

• Management remains confident in the risk-reward profile, emphasizing EPS growth and shareholder value.